Suppr超能文献

取代苯并咪唑类药物匹考拉唑对胃(H⁺+K⁺)-ATP酶的抑制作用

Inhibition of gastric (H+ + K+)-ATPase by the substituted benzimidazole, picoprazole.

作者信息

Wallmark B, Sachs G, Mardh S, Fellenius E

出版信息

Biochim Biophys Acta. 1983 Feb 9;728(1):31-8. doi: 10.1016/0005-2736(83)90433-9.

Abstract

The substituted benzimidazole, picoprazole, inhibited the gastric (H+ + K+)-ATPase in a concentration-and time-dependent manner. Half-maximal inhibition of the (H+ + K+)-ATPase activity was obtained at about 2 . 10(-6)M under standard conditions. In addition to the inhibition of ATPase activity, parallel inhibition of phosphoenzyme formation and the proton transport activity were achieved. Radiolabelled picoprazole was found to bind to 100 kDa peptide; this peptide was shown by phosphorylation experiments to contain the catalytic centre of the (H+ + K+)-ATPase. Studies on the (Na+ + K+)-ATPase indicated that this enzyme was unaffected by picoprazole. From the data presented and from other pharmacological studies, it is proposed that this compound inhibits acid secretion at the level of the parietal cell by its ability to inhibit the gastric proton pump, the (H+ + K+)-ATPase.

摘要

取代苯并咪唑类药物匹考拉唑以浓度和时间依赖性方式抑制胃(H⁺ + K⁺)-ATP酶。在标准条件下,约2×10⁻⁶M时可获得(H⁺ + K⁺)-ATP酶活性的半数最大抑制。除了抑制ATP酶活性外,还实现了对磷酸化酶形成和质子转运活性的平行抑制。发现放射性标记的匹考拉唑与100 kDa肽结合;磷酸化实验表明该肽含有(H⁺ + K⁺)-ATP酶的催化中心。对(Na⁺ + K⁺)-ATP酶的研究表明该酶不受匹考拉唑影响。根据所提供的数据和其他药理学研究,推测该化合物通过抑制胃质子泵即(H⁺ + K⁺)-ATP酶的能力,在壁细胞水平抑制胃酸分泌。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验